Day One Biopharma Earnings Call Highlights Ojemda Surge

Day One Biopharmaceuticals, Inc. ((DAWN)) has held its Q4 earnings call. Read on for the main highlights of the call.

Day One Biopharmaceuticals struck an upbeat tone on its latest earnings call, underscoring rapid uptake of flagship drug Ojemda, strong revenue growth, and a fortified balance sheet. Management balanced this optimism with a sober view of pediatric safety monitoring, single‑product reliance, and multi‑year timelines for pipeline assets, leaving investors weighing strong execution against execution and timing risks.

Explosive Full-Year Revenue Growth from Ojemda

Day One reported 2025 net product revenue of $155.4 million, a 172% jump versus 2024 as Ojemda’s launch matured. Revenue has grown fast enough that, within about 20 months of approval, sales exceeded the combined cost of sales and SG&A, signaling a move toward operating leverage despite a still‑young commercial franchise.

Q4 Surge Caps a Breakout Commercial Year

Fourth-quarter 2025 U.S. Ojemda revenue reached $52.8 million, up 37% sequentially from Q3 and highlighting accelerating momentum into year‑end. Prescriptions in Q4 topped 1,300, an 11% increase despite typical holiday seasonality that often dampens oncology prescribing patterns.

Rapid Adoption and Rising Prescription Volumes

For 2025, Ojemda generated more than 4,600 total prescriptions, over 180% higher than in 2024 as physicians increasingly incorporated the drug into practice. New patient starts in the back half of 2025 climbed about 25% versus the first half, suggesting broadening awareness and stronger confidence among treating oncologists.

Management Reaffirms Ambitious 2026 Revenue Targets

The company reiterated its 2026 U.S. Ojemda revenue forecast of $225 million to $250 million, with the midpoint implying more than 50% growth over 2025. Executives emphasized that performance within this range will hinge mainly on persistence, with median commercial treatment duration trending around 19 months, and on sustaining a healthy pace of new starts.

Payer Coverage Supports Fast, Predictable Access

Day One highlighted highly favorable reimbursement dynamics for Ojemda, with about 95% of covered lives and more than 90% of patients approved on first request. Over 95% of eligible pLGG patients are receiving paid drug, limiting reliance on free‑drug programs and enabling rapid time‑to‑therapy, a key driver of revenue visibility.

Robust Cash Position and Added Firepower from Mersana Deal

The company ended 2025 with roughly $441 million in net cash and no debt, giving it ample capital to fund commercialization and development plans. In January 2026, Day One closed its acquisition of Mersana, bringing in the EMILY antibody–drug conjugate program as a potential second growth pillar.

FIREFLY-1 Data Reinforce Ojemda’s Clinical Value

Three‑year FIREFLY‑1 results showed a 53% objective response rate, essentially in line with the 51% at approval, with median response duration of 19.4 months and median time to response of 5.4 months. Median progression‑free survival was 16.6 months and median time‑to‑next‑treatment was a notable 42.6 months, while 45% of patients who initially progressed later saw further tumor shrinkage on continued therapy.

Pipeline Progress: EMILY and DAY301 Take Shape

EMILY, a B7‑H4–targeted ADC acquired with Mersana, has shown monotherapy activity in adenoid cystic carcinoma, with a larger data update and expanded safety set expected in mid‑2026 to inform its registrational strategy. DAY301, a PTK7‑targeted ADC in dose escalation, has early antitumor signals and is slated for a program update in 2026, though it remains at an earlier, higher‑risk stage.

Improving Cost Discipline and Operating Efficiency

Total costs and operating expenses fell to $286 million in 2025 from $348 million in 2024, aided by the absence of prior‑year in‑licensing charges. Fourth‑quarter operating expenses declined to $81 million from $95 million a year earlier, suggesting Day One is finding room to scale Ojemda while containing overhead and development spending.

Managing Safety in a Pediatric Population

Management stressed that Ojemda’s three‑year safety profile remains consistent with its label but requires active monitoring in children. Higher‑grade events such as decreased growth velocity, anemia, occasional more severe rash, and asymptomatic lab abnormalities like elevated CPK or ALT will demand ongoing vigilance and could influence physician comfort and treatment duration.

Single-Product Dependence Elevates Concentration Risk

Ojemda remains the company’s sole commercial engine and primary growth driver, creating concentration risk until other programs mature. Investors will be watching for EMILY and DAY301 to de‑risk and eventually contribute revenue, as any slowdown or competitive pressure on Ojemda could disproportionately affect the company’s financial profile.

Rising Gross-to-Net Headwinds Ahead

Gross‑to‑net discounts on Ojemda were within the 12%–15% range in 2025, but management now guides to 16%–19% for 2026. That step‑up in rebates and other adjustments could weigh on margins even if top‑line demand remains strong, putting a premium on cost control and volume growth to preserve profitability trajectory.

Limited Near-Term Commercial Impact from Conference Data

The company noted that the SNO presentation of three‑year FIREFLY‑1 data had little immediate effect on Q4 results, given limited promotional freedom before peer‑reviewed publication. Broader physician adoption and deeper penetration are expected to rely on full publication and wider dissemination of the data, slightly delaying the commercial payoff of the strong efficacy profile.

Pipeline and Regulatory Timelines Stretch Revenue Diversification

Key development milestones remain several years out, with FIREFLY‑2 enrollment slated to finish in the first half of 2026 and top‑line data not expected until mid‑2027. EMILY’s regulatory path will depend on mid‑2026 data and subsequent agency discussions, while DAY301 is still in dose escalation, leaving the company reliant on Ojemda for the foreseeable future.

EMILY Targets a Small but Strategic ACC Market

EMILY’s lead indication, adenoid cystic carcinoma, represents a small niche of roughly 1,300 U.S. diagnoses per year, limiting the near‑term revenue ceiling even if an accelerated path emerges. The rarity of ACC raises the bar for clear, robust single‑arm data and makes the quality of mid‑2026 results critical for both regulatory prospects and investor confidence.

Guidance Underscores Confidence but Flags Margin Pressure

Day One’s reiterated 2026 Ojemda revenue range of $225 million to $250 million, building on 2025’s 172% growth and strong Q4 prescription trends, signals confidence in durable demand. At the same time, assumptions of higher gross‑to‑net levels, stable channel inventory, and continued pediatric safety management frame a guidance backdrop where volume and persistence must offset rising discount headwinds.

Day One’s earnings call painted the picture of a young oncology company executing well on a single successful launch while carefully laying groundwork for its next act. For investors, the story hinges on Ojemda’s continued momentum, effective handling of pediatric risks, and timely, de‑risking data from EMILY and DAY301 that can eventually broaden the revenue base beyond one standout product.